Login
Israel-Hamas Conflict
World Cup
Social Media
Boxing
Military
War
Benjamin Netanyahu
South America
Artificial Intelligence
Donald Trump
Natural Disasters
Immigration
Instagram
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

ILCN.org (ILCN/WCLC) image

News from ILCN.org (ILCN/WCLC)

If you want to know if ILCN.org (ILCN/WCLC) is credible or reliable, look no further. We rank ILCN.org (ILCN/WCLC) as Unknown factuality. Find out more about our methodology here.

Information about ILCN.org (ILCN/WCLC)

Where is ILCN.org (ILCN/WCLC) located?ILCN.org (ILCN/WCLC)'s Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ILCN.org (ILCN/WCLC) News

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC
Medical · United States

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Coverage: 2 sources
The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.See the Story
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy - ILCN.org (ILCN/WCLC)
Maryland · Maryland

Rethinking Radiation: Adopting Hypofractionated Radiation Therapy - ILCN.org (ILCN/WCLC)

Puneeth Iyengar, MD, PhD, and Edward Christopher Dee, MD, recently discussed the environmental costs of cancer treatment in an interview with ILCN. In part two of our series, Dr. Iyengar, a radiation oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), New York, and Dr. Dee, a third-year resident at MSKCC, explore the benefits and challenges of adopting hypofractionated radiation schedules. Puneeth Iyengar, MD, PhD ILCN: What is hypofr…Read Article
Global Insights into Smoking Cessation in Lung Cancer Screening - ILCN.org (ILCN/WCLC)
United States · United States

Global Insights into Smoking Cessation in Lung Cancer Screening - ILCN.org (ILCN/WCLC)

Rachael Murray, PhD, MS, BSc Smoking cessation interventions are a critical component of lung cancer screening (LCS) programs, as they have been shown to reduce smoking-related risks and improve screening outcomes. Evidence increasingly supports the inclusion of high-intensity and opt-out smoking cessation services at the point of screening as having the greatest impact. Despite this, the implementation of cessation support within LCS programs v…Read Article

Gene Assay May Guide Chemo Use in Early NSCLC: ASCO 2025

A 14-gene molecular assay may help identify early-stage non-squamous NSCLC patients who benefit from chemotherapy post-surgery, potentially guiding adjuvant treatment decisions.See the Story

Overcoming Resistance Remains a Challenge in Targeting KRAS - ILCN.org (ILCN/WCLC)

Alice Shaw, MD, PhD For several decades, RAS has been considered a potent oncogenic driver; however, until the development of KRAS G12C inhibitors, it was deemed “undruggable.” “This early success with G12C inhibitors, along with additional key insights into targeting RAS, has fueled this explosion and drug discovery, with numerous new RAS inhibitors now in preclinical and clinical development,” said Alice Shaw, MD, PhD, on April 28 during a ses…Maryland · MarylandRead Article

Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does? - ILCN.org (ILCN/WCLC)

Immune checkpoint inhibitors (ICIs) are largely considered a game-changer for patients with non-small cell lung cancer (NSCLC), delivering survival benefits in both early and advanced stages of the disease. However, between 3% and 12% of patients treated with a single ICI, and up to 25% of patients treated with immunotherapy combinations, must discontinue treatment due to immune-related adverse events (irAEs). Mark Awad, MD, PhD “When immunothe…Maryland · MarylandRead Article

Falling Through the Cracks: Battling Barriers in Lung Cancer Care - ILCN.org (ILCN/WCLC)

Inspired by both the call to help people during their worst days and the excitement of the role, Daiyo Ito decided to make a major career shift nearly 7 years ago from a branch manager at a rental car agency to a firefighter with the Pasadena Fire Department. Since then, Mr. Ito has responded to wildfire outbreaks across California, but things were different in January 2025 when the Los Angeles County Wildfires erupted across the region. Mr. Ito…Maryland · MarylandRead Article

Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs - ILCN.org (ILCN/WCLC)

The final survival data from a phase IIa clinical trial revealed that the investigational treatment CAN-2409 may extend survival beyond standard-of-care docetaxel when combined with continued immune checkpoint inhibitor (ICI) treatment, according to a press release from the manufacturer Candel Therapeutics Inc.1 Key Findings According to the data, the median overall survival (mOS) among patients with advanced non-small cell lung cancer (NSCLC) w…ResearchRead Article

FDA OKs New Drug for Lung Cancer With c-Met Overexpression

100% Center coverage: 1 sources
(MedPage Today) -- The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein...FDA · United StatesSee the Story

A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going - ILCN.org (ILCN/WCLC)

The Closing Keynote at the 2025 Hot Topics in Small Cell Lung Cancer (SCLC) centered around four decades of research in the field. Anish Thomas, MBBS, MD, began by inviting attendees to be inspired by the vision and scientific clarity that has defined the past 40 years of SCLC research, before introducing the keynote speaker, John D. Minna, MD. John D. Minna, MD This session and other meeting coverage is available on demand via Lung Cancer 360 …Dallas, Texas · DallasRead Article

In Brief for May 14, 2025 - ILCN.org (ILCN/WCLC)

Health Canada has approved the combination of pembrolizumab with chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This represents Canada’s first approved pembrolizumab-chemotherapy combination regimen for patients with MPM. The decision was based on findings from the IND.227/KEYNOTE-483 trial, which revealed statistically significant improvements in overall survival (OS), overall …Health Canada · CanadaRead Article

Breaking News Topics Related to ILCN.org (ILCN/WCLC)

Wildfires

Wildfires

Cancer

Cancer

Texas, United States

Texas, United States

Natural Disasters

Natural Disasters

Maryland

Maryland

United States

United States

News
For You
SearchBlindspotLocal